hma

5-(N,N-Hexamethylene)-amiloride (5-HMA) is an amiloride derivative that inhibits TRPA1-mediated calcium signaling (IC50: 35 μM). It functions as an inhibitor of the Na+/H+ exchanger (NHE) with Ki values ranging from 0.013 to 2.4 μM for various NHE isoforms. Additionally, 5-HMA blocks ASIC3 channels by 51% at 20 μM.

Antiasthmatic Compound 1 is an antiasthmatic agent.

hMAO-B-IN-32 is a potent hMAO-B selective inhibitor with an IC50 of 45.52 μM.

Asthma relating compound 1 is a potential anti-asthma compound.

hMAO-B-IN-4 is a selective, reversible and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B, IC50=0.067 μM, Ki= 0.03 μM, hMAO-A, IC50= 33.82 μM).

Rehmaneolignan A is a useful organic compound for research related to life sciences. The catalog number is T125420 and the CAS number is 2001061-00-1.

Daphmacrine is a natural product that can be used as a reference standard.

Compound 17k, also known as Antileishmanial agent-30, effectively inhibits Leishmania with an IC50 of 0.2 μM for L. donovani. It exhibits a CC50 of >100 μM and an SI of >500, indicating significant selectivity and potency.

hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 values of 424.1 nM and 177.9 nM, respectively. It has demonstrated neuroprotective effects in the MPTP-induced mouse model of Parkinson's Disease (PD).

Antileishmanial agent-31 (Compound p1) is a pyrazole derivative exhibiting antileishmanial activity with an IC50 of 35.53 μg/mL. Furthermore, Antileishmanial agent-31 demonstrates high stability and is applicable in studies focused on leishmaniasis treatment.

3,4-DHMA (3,4-Dihydroxymethamphetamine) TFA is an active metabolite of 3,4-MDMA.

Antileishmanial agent-33 (4e) is a hybrid compound of grandisin and machilin G, demonstrating moderate activity against promastigotes with an IC50 of 38.1 μM. In studies of cutaneous leishmaniasis (CL), Antileishmanial agent-33 (4e) has shown potential as an antileishmanial agent.

hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 0.11 µM. It operates by competitively binding to the active site of hMAO-B, thereby preventing the oxidative deamination of monoamines and reducing hydrogen peroxide production. Additionally, hMAO-B-IN-11 inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia. This compound holds potential for research in neurodegenerative diseases such as Parkinson's and Alzheimer's.

Antileishmanial agent-26 (Compound 69) is a guanidine-containing compound with activity against *Leishmania donovani*, exhibiting an IC50 value of 5.67 μM and a CC50 value of 3.79 μM in THP-1 cells. This compound is applicable for research in tropical diseases.

Antileishmanial agent-27 (compound 7j) is a benzothiazole-coumarin derivative. It acts as a competitive inhibitor of arginyl-tRNA synthetase (ArgRS). This compound demonstrates selectivity towards the Leishmania donovani ArgRS (LdArgRS) over the human counterpart (HsArgRS), with IC50 values of 1.2 μM and 19 μM, respectively. Additionally, Antileishmanial agent-27 exhibits favorable pharmacokinetic properties.

Antileishmanial agent-29 (Compound 110) is an orally active compound that exhibits antileishmanial properties. It can protect mice from Leishmania infection when administered orally at doses of 40 or 60 mg/kg over a period of 10 days.

hMAO-B-IN-8 (Compound 23) is an inhibitor of hMAO-B, eeAChE, COX-2, and 5-LOX, with IC50 values of 0.037 μM, 0.071 μM, 14.3 μM, and 0.59 μM, respectively. This compound is utilized in research related to Alzheimer's disease.

Antileishmanial agent-34 (Fig. (9), compound 3) is an aurone with activity against Leishmania parasites. It is effective against extracellular forms Lmaj, Ldon, Linf, and Lenr, as well as the intracellular form of Ldon (IC50 < 2 µg/mL).

Antileishmanial agent-35 (Compound 6) is an antileishmanial compound with an IC50 of 0.29 μM against the promastigotes of Leishmania amazonensis. It acts by disrupting the electron transport chain (where ubiquinone plays a role), markedly reducing mitochondrial membrane potential and ATP levels, and increasing reactive oxygen species (ROS) production. Antileishmanial agent-35 is applicable in the study of cutaneous leishmaniasis.

Antileishmanial agent-37 (Compound 1b) is an antileishmanial agent and acts as an inhibitor of TbPTR1 (IC50 value of 17.1 μM) and LmPTR1. It exhibits moderate efficacy against Leishmania infantum.

hMAO-B-IN-12 (Compound 6E) is a highly selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 17.7 nM. It reduces products generated by oxidative stress/lipid metabolism, such as H2O2, and has potential applications in atherosclerosis research.

Antileishmanial agent-38 (compound 197) is a host-targeted small molecule exhibiting potent broad-spectrum activity against Leishmania spp. This compound primarily works by targeting host protein lysozyme to inhibit intracellular parasites and also shows direct activity against extracellular L. donovani promastigotes. Antileishmanial agent-38 is applicable in leishmaniasis research.

Antileishmanial agent-39 (Compound 4h) is an agent effective against Leishmania parasites. It shows antileishmanial activity against the axenic amastigote form of Leishmania infantum, with an IC50 value of 0.42 μM.

Rehmannioside C is an iridoid glucoside. Rehmannioside C has been isolated from Radix Rehmanniae Praeparata[1].